Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report. Issue 5 (16th April 2019)

• Record Type: Journal Article
• Authors: Nishikawa, Yotaro; Mochida, Kosuke; Kubo, Tamaki; Horikawa, Nagako; Nemoto, Rieko; Amano, Masahiro
• Is Part Of: Clinical case reports. Volume 7:Issue 5(2019)
• Page Start: 1057
• Page End: 1061
• Publication Date: 2019-04-16
• Subjects: adult T-cell leukemia/lymphoma -- CC chemokine receptor 4 -- graft-vs-host disease -- mogamulizumab -- smoldering type; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2155
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft‐vs‐host disease. However, refractory specific skin lesions of smoldering type adult T‐cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case. Abstract : The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft‐vs‐host disease. However, refractory specific skin lesions of smoldering type adult T‐cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case.